Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?

Novel cardioprotective agents are needed in both heart failure (HF) and myocardial infarction. Increasing evidence from cellular studies and animal models indicate protective effects of phosphodiesterase-5 (PDE5) inhibitors, drugs usually reserved as treatments of erectile dysfunction and pulmonary...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutchings, David Charles, Anderson, Simon George, Caldwell, Jessica L, Trafford, Andrew W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204975/
https://www.ncbi.nlm.nih.gov/pubmed/29519873
http://dx.doi.org/10.1136/heartjnl-2017-312865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204975/
https://www.ncbi.nlm.nih.gov/pubmed/29519873
http://dx.doi.org/10.1136/heartjnl-2017-312865

Ejemplares similares